Searchable abstracts of presentations at key conferences in endocrinology

ea0011p40 | Bone | ECE2006

Does parathyroidectomy reduce the risk of fractures and renal stones? Results of a systematic review and meta analysis

Sanders BE , Davies M , Selby PL

Primary hyperparathyroidism (PHP) is a common endocrine condition. The associated metabolic abnormalities are usually amenable to surgical treatment (PTX). Although it is generally believed that such treatment will reduce the risk of long-term complications this has not been demonstrated in a clinical trial and the current treatment guidelines are based on consensus. In order to assess the effect of parathyroidectomy on two of the most common complications of PHP, renal stones...

ea0012p78 | Pituitary | SFE2006

Upregulation of Id1 and Id3 in response to BMP2 stimulation in LβT2 cells

Hanson PL , Sidhu KK , Schwarz N , Milligan T , Burrin JM

The pathogenesis of gonadotrophin secreting pituitary tumours (gonadotrophinomas) remains poorly understood. Bone morphogenetic proteins (BMPs) are important for the control of cell proliferation and differentiation and BMP2 is essential for commitment of undifferentiated pituitary cells to the gonadotroph cell lineage. In addition, BMPs have been implicated in tumourigenesis in a variety of tissues, associated with up-regulated expression of Id (Inhibitors of differentiation)...

ea0011p69 | Clinical case reports | ECE2006

Primary hyperparathyroidism (PHPT): Still a cause of hypertension resistant to therapy

Baptista AP , Morgado EC , Silva AP , Neves PL

High blood pressure is a common problem among patients in a Nephrology ward and outpatient clinic. However in those patients resistant to therapy, we must exclude a secondary cause. The authors present a case of a patient that was referred to our hospital due to complaints of headache, high blood pressure resistant to therapy (BP=240/130 mmHg), and images in renal ecography, which were compatible with enlarge left adrenal gland and left kidney atrophy. At admission the blood r...

ea0008p44 | Endocrine Tumours and Neoplasia | SFE2004

Expression of Bone Morphogenetic Protein receptors in human pituitary adenomas

Brown PL , Stoddart HL , Sidhu KK , Milligan TP , Burrin JM

Bone morphogenetic proteins (BMPs) regulate growth, differentiation and apoptosis in a variety of tissues and have crucial roles in the regulation of reproduction. BMPs bind specific Type II receptors and form complexes with Type I receptors (Alk2, 3 or 6) whereby the Type II receptors activate Type I receptors by phosphorylation. BMP2 and 4 play a crucial role in the development of the gonadotroph cell lineage during mouse pituitary morphogenesis and BMP6, 7, and 15 stimulate...

ea0016p302 | Endocrine tumours | ECE2008

Impact of the use of recombinant TSH stimulated thyroglobulin measurement on health related quality of life in patients in follow-up for differentiated thyroid carcinoma (DTC)

Persoon ACM , Sluiter WJ , Jager PL , Ranchor AV , Wolffenbuttel BHR , Links TP

Introduction: Thyroglobulin (Tg) measurement is the cornerstone in the follow-up of DTC. Sensitivity can be optimised by measuring recombinant TSH stimulated Tg (rhTSH-Tg). Higher sensitivity results in more Tg positive patients who need imaging and considerable patient burden. We assessed the impact of rhTSH-Tg measurement on health related quality of life (HRQOL).Methods: In 121 patients in follow-up for DTC, Tg during thyroid hormone suppression thera...

ea0014oc9.6 | Signal transduction | ECE2007

Somatostatin receptor subtype-2 and -3 – selective agonists inhibit insulin secretion from INS-1 cells through modulation of the R-type Ca2+ channel

Mergler Stefan , Singh Vandana , Zacharias Sylvia , Wiedenmann Bertram , Plöckinger Ursula , Strowski Mathias

Objectives: Somatostatin (SST) inhibits insulin secretion from pancreatic B-cells through a reduction of intracellular free calcium ([Ca2+]i). The influx of Ca2+ is mediated by voltage-operated Ca2+ channels (VOCCs). The role of VOCCs of the R-type (CaV2.3) in SST-mediated processes is unknown. Therefore, we designed a study to identify SST-receptor subtypes (SSTR) in insulinoma cells (INS-1) and characterize the role of t...

ea0014p252 | (1) | ECE2007

Somatostatin receptor subtype 2 inhibits glucagon secretion and regulates glucose homeostasis

Strowski Mathias , Singh Vandana , Grötzinger Carsten , Zacharias Sylvia , Wiedenmann Bertram , Plöckinger Ursula

Objectives: Somatostatin (SST) inhibits glucagon and insulin secretion. Five receptor subtypes for SST are known (SSTR1-SSTR5), all of which are expressed in the endocrine pancreas. SSTR2 inhibits glucagon secretion in vitro, however its role in vivo is not well understood. Here, we characterize the role of SSTR2 in regulating glucose homeostasis in mice with diet-induced obesity.Methods: SSTR2-deficient (SSTR2−/−) and control mice...

ea0012oc7 | Young Endocrinologist prize session | SFE2006

T3 stimulation of MAP kinase and cell proliferation in human osteoblast-like cells is initiated at integrin αVβ3

Scarlett AL , Parsons MP , Hanson PL , Sidhu KK , Milligan TP , Burrin JM

T3 and T4 rapidly activate intracellular signalling cascades via thyroid hormone receptor (TR)-independent actions, suggesting the existence of a plasma membrane receptor. Recent studies support a role for the RGD recognition site of integrin, a transmembrane glycoprotein, as a cell surface TR. We have demonstrated, using PCR and Western blotting, the expression of integrin αVβ3 mRNA and protein in the transformed human osteosarcoma cell line MG...

ea0012oc15 | Placenta, bone and genetics | SFE2006

Preliminary results from the PRISM study: a multicentre randomised controlled trial of intensive vs. symptomatic management for Paget’s disease of bone

Ralston SH , Langston AL , Campbell MK , MacLennan G , Selby PL , Fraser WD

Bisphosphonates are the treatment of choice for Paget’s disease of bone (PDB). However, long-term effects on complications are unknown. The PRISM trial was a randomised controlled trial comparing symptomatic management and intensive bisphosphonate therapy for PDB, and involved 1324 patients followed for a median of 32 months (range 12–48). Patients allocated to symptomatic therapy (n=663) were untreated unless they had bone pain, at which point they received a...

ea0011oc18 | Clinical endocrinology | ECE2006

Endoscope-assisted pituitary surgery for functioning and non-functioning pituitary adenomas. The experience of the first 80 patients in a single centre

Hanson PL , Joshi SM , Alusi G , Sabin HI , Drake WM , Monson JP

Introduction: We present the outcome for the first 80 patients undergoing neuronavigation–guided, endoscopic transphenoidal surgery in our centre since August 2001. All operations were undertaken by the same neurosurgeon and endoscopic nasal surgeon.Indications for treatment: Indications for treatment may be divided into: Functioning microadenomas, with the aim of surgical cure while protecting residual pituitary function. Functioning macroadenomas,...